Home › Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe
 

Keywords :   


Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe

2014-05-19 23:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. Language: English Contact: MerckMedia:Ian McConnell, +1 908-423-3046orClaire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465orJustin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292orTony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more

Tags: in marketing europe applications

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11 DVD-BOX5
15.11 100
15.11NIKE X (27)
15.11 MEMORIA8 HOOD Towel
15.1119HGLEFT
15.11
15.11X-PLUS
15.11 BoU CD
More »